Sanofi and Scribe’s expanded deal builds path to in vivo editing in SCD
The pharma’s nanoparticle delivery technology is at the core of the collaboration
Scribe and Sanofi’s extension of their collaboration beyond ex vivo cell therapies to in vivo gene editing was precipitated by the pharma’s emerging capacity to deliver nucleic acids outside the liver.
On Monday, Scribe Therapeutics Inc. announced it was granting Sanofi (Euronext:SAN; NASDAQ:SNY) an exclusive license to use its CRISPR X-Editing technology to develop in vivo therapies, including for sickle cell disease (SCD). ...